Moderna to Seek U.S., EU Clearance for Covid Vaccine

Moderna to Seek U.S., EU Clearance for Covid Vaccine

Assessment

Interactive Video

Business, Health Sciences, Biology

University

Hard

Created by

Quizizz Content

FREE Resource

The transcript discusses the current state of COVID-19 vaccine efficacy, highlighting a 94.4% effectiveness rate. It notes the absence of severe cases among the elderly, suggesting high efficacy. The market's lack of reaction to this news is mentioned, along with the challenges of accelerating vaccine production and distribution. The potential for other companies, like Nova VAX, to contribute to positive developments is also discussed, as well as the logistics of vaccine rollout and the timeline for achieving critical mass inoculation.

Read more

5 questions

Show all answers

1.

MULTIPLE CHOICE QUESTION

30 sec • 1 pt

What is the reported efficacy rate of the COVID-19 vaccine based on the analysis of 196 cases?

92.3%

90.0%

96.1%

94.4%

2.

MULTIPLE CHOICE QUESTION

30 sec • 1 pt

What does the absence of severe cases among the elderly suggest about the vaccine?

It causes mild side effects.

It is ineffective for older adults.

It requires multiple doses for effectiveness.

It has 100% efficacy against severe cases.

3.

MULTIPLE CHOICE QUESTION

30 sec • 1 pt

What is a major challenge in accelerating the vaccination schedule?

Lack of public interest

Insufficient vaccine doses

Complex approval processes

High production costs

4.

MULTIPLE CHOICE QUESTION

30 sec • 1 pt

Which company is mentioned as potentially contributing to future positive vaccine results?

Johnson & Johnson

Nova VAX

Moderna

Pfizer

5.

MULTIPLE CHOICE QUESTION

30 sec • 1 pt

What recent development is noted about Nova VAX's UK trials?

They have canceled recruitment.

They have paused recruitment.

They have completed recruitment.

They have started recruitment.